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iron appears to be an economically viable treatment option 
in anemic cancer patients. Additional research on ESA dose 
savings and cost-effectiveness is required. 
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 Background 
 Anemia is a common condition in cancer patients, es-
pecially when receiving chemotherapy  [1] . It substantial-
ly increases treatment costs  [2, 3] and affects the quality 
of life  [4] . Health state utility scores of 0.48–0.56 for sub-
jects with severe anemia compare to scores of patients 
with metastatic disease  [5, 6] .
 Erythropoiesis-stimulating agents (ESAs) are an ap-
proved treatment option in anemic cancer patients re-
ceiving chemotherapy  [7, 8] ; however, ESA costs are high 
and a health technology assessment estimated incremen-
tal cost-effectiveness ratios (ICERs) of GBP 40,000–
150,000 per quality-adjusted life year gained  [5] . Further-
more, safety concerns limit their use  [8] . Thus, the EMA 
indicates a need for caution  [9] and the US FDA requires 
a Risk Evaluation and Mitigation Strategy (REMS)  [10] .
 Optimization of iron stores with intravenous (i.v.) iron 
supplementation of ESA therapy significantly improved 
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 Abstract 
 Background: Intravenous (i.v.) iron supplementation signifi-
cantly improves the response to erythropoiesis-stimulating 
agent (ESA)-based therapies in patients with cancer- or che-
motherapy-induced anemia. The economic implications of 
adding i.v. iron to ESA treatment are less well investigated. 
Published randomized controlled trials do not provide suf-
ficient data for a comprehensive cost-effectiveness analysis. 
 Methods: Preliminary cost calculations from the Swiss health 
care system perspective based on a meta-analysis and pub-
lished results of eight randomized controlled trials without 
correction for decreased ESA need provide a conservative 
cost-effectiveness estimate.  Results: The additional total 
cost of i.v. iron supplementation ranged from EUR 417 to EUR 
901 per patient depending on the evaluated iron-carbohy-
drate complex. Considering a 24% absolute increase in the 
proportion of ESA responders, the incremental cost-effec-
tiveness ratios per additional responder are EUR 1,704–3,686. 
In routine practice, better values may be achieved due to ESA 
dose savings.  Conclusion: Supplementation of ESAs with i.v. 
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the hemoglobin response in patients with cancer- or che-
motherapy-induced anemia (CIA)  [11–18] . However, little 
is known about the economic implications of adding i.v. 
iron to ESAs in this indication.
 We report a preliminary economic assessment of i.v. 
iron supplementation in ESA-treated anemic cancer pa-
tients from the Swiss health care perspective.
 Methods 
 A systematic review and meta-analysis of studies on i.v. iron 
supplementation of ESAs in patients with CIA was used as a basis 
for this study  [19] . The meta-analysis included eight studies on i.v. 
iron versus no or oral iron supplementation that were reported 
until 2010 (hematopoietic response defined as an increase in he-
moglobin of  1 2 g/dl or above 12 g/dl)  [19] . Information on re-
sponse rates was retrieved from the meta-analysis, and dosages of 
i.v. iron and ESAs were taken from published results of the indi-
vidual studies  [11–14, 16–18, 20] and pooled and weighted accord-
ing to study size.
 Equal efficacy of different i.v. iron preparations was assumed. 
In absence of data on actual ESA dose adjustment, our conserva-
tive cost model also assumed that the initial ESA dosage would be 
maintained over the entire treatment period.
 Drug treatment costs were assessed from the perspective of the 
Swiss health care system. The ESA cost per patient was based on 
the publicly reimbursed price of relevant ESA preparations [pro-
portional use in Switzerland: epoetin alfa 9%, epoetin beta 35%, 
darbepoetin alfa 56% (IMS Midas 2010-Q1)]. Costs of ferric glu-
conate (FG; EUR 11.39), iron dextran (EUR 20.51), iron sucrose 
(EUR 22.78), and ferric carboxymaltose (FCM; EUR 27.84) were 
based on the publicly reimbursed price per 100 mg iron. Since iron 
dextran and FG are not available on the Swiss market, prices were 
assumed to be 10 and 50% lower than the price of iron sucrose 
(based on experience with other markets and the Swiss pricing 
system), respectively. Administration costs of different i.v. iron 
preparations were derived from the official Swiss tariff list ( ta-
ble 1 ; http://onb.tarmedsuisse.ch/)  [21] .
 Cost implications and ICERs were estimated relative to the 
reference case of no i.v. iron use. Drug and administration costs 
are valid for the year 2011 and are shown in euros (1 EUR = 1.273 
CHF, May 2011). 
 Results 
 Eight relevant randomized controlled trials of i.v. iron-
supplemented ESA treatment included 1,555 anemic can-
cer patients. The weighted mean proportion of respond-
ers to ESA therapy was 84% in the i.v. iron arms compared 
to 60% in the reference arms (+24%). On average, 1,191 
mg i.v. iron were administered over a mean observation 
period of 13.97 weeks. Mean i.v. iron doses ranged from 
600 to 2,000 mg and were generally well tolerated. Apart 
from one study  [11] , all trials adjusted ESA doses depend-
ing on hemoglobin values, but only one  [16] reported total 
ESA doses.
 The ESA cost per patient during the observation pe-
riod was EUR 8,196. The additional total cost per patient 
of i.v. iron supplementation ranged from EUR 417 (FCM) 
to EUR 901 (FG) including estimated administration 
costs of EUR 85 (FCM) and EUR 766 (FG), respectively 
(estimates for 1,191 mg). The 24% increment in hemoglo-
bin response with i.v. iron versus no or oral iron supple-
Table 1. A ssumed input parameters based on the official Swiss tariff list (TARMED)
TARMED reference No. EURa
Consultation first 5 min 00.0010 12.29
Consultation next 5 min (max 2!) 00.0020 12.29
Consultation last 5 min 00.0030 12.29
Small clinical examination (e.g. height, weight) 00.0410 39.24
Injection/infusion by nonmedical staff 00.0750 5.67
Cost of administration of i.v. iron
Push i.v. injection 00.0010 + 00.0030 + 00.0750 30.24
Slow i.v. injection (2 min) 00.0010 + 00.0030 + 00.0750 30.24
Slow i.v. injection (15 min) 00.0010 + 00.0020 + 00.0030 + 00.0750 42.53
i.v. infusion (<1 h) 00.0010 + 2 ! 00.0020 + 00.0030 + 00.0750 54.82
i.v. infusion per hour (pro rata temporis) Hosp 35.89
Hospitalization (1 day) Hosp 861.32
If a test dose injection is needed, add 00.0410 39.24
a  One TARMED point is reimbursed with EUR 0.69.
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mentation corresponded to ICERs of EUR 1,704, EUR 
2,187, EUR 2,455, and EUR 3,686 per additional respond-
er for FCM, iron dextran, iron sucrose, and FG, respec-
tively.
 Discussion 
 A recent meta-analysis of randomized controlled 
clinical trials on i.v. iron supplementation of ESA ther-
apy in anemic cancer patients summarized the im-
proved hematologic response versus no or oral iron sup-
plementation  [19] . However, published data do not in-
clude i.v. iron-associated ESA dose reduction. Therefore, 
our calculations are based on a conservative approach 
assuming a constant ESA dosage over the treatment pe-
riod. However, in routine practice, ESA administration 
would likely be delayed or reduced upon hematologic 
response to i.v. iron supplementation. In anemic patients 
with lymphoid malignancies who did not receive che-
motherapy, a 25% reduction of weekly mean ESA dos-
ages at the end of a 16-week treatment period and over-
all cost savings of 11% over the entire treatment period 
were reported  [16, 22] .
 Under our conservative assumption, the addition of 
i.v. iron to ESA treatment of CIA patients would lead to 
a cost of EUR 1,704–3,686 per additional responder to 
ESA treatment. Given the use of the ‘metric’ of addition-
al responders in the denominator of the cost effective-
ness equation (representing clinical effectiveness in the 
absence of alternatives), this result needs the following 
discussion. A more comprehensive assessment of the 
cost-effectiveness of i.v. iron supplementation would re-
quire data on associated ESA dose reductions. Notably, a 
former cost analysis based on a single study in 60 patients 
with CIA estimated savings of USD 1,300 per i.v. iron-
supplemented patient  [23] . In addition, blood transfu-
sion requirements may be reduced upon i.v. iron admin-
istration to anemic cancer patients  [13, 19, 24, 25] and 
further increase the cost benefit of i.v. iron. However, giv-
en insufficient data on the use of blood transfusions, we 
did not consider this aspect in our calculations. Clinical 
studies of i.v. iron at recommended doses  [26] did not 
show unexpected AEs  [11–14, 16–18, 20, 27] . Long-term 
studies are warranted, yet preliminary data on i.v. iron 
supplementation of ESA-treated patients showed no ef-
fect on 3-year progression-free survival  [14, 28] . Costs of 
management of potential AEs were not included in our 
analysis. The economic results presented here reflect the 
perspective of the Swiss health care system as a mainly 
third party payer-funded health care system. The results 
may be indicative for markets with similar health care 
systems, although the underlying health economic mod-
els will need adjustment before they can be applied to 
other countries. The model may also need some adaption 
when biosimilars of ESAs become available at reduced 
costs.
 The main cost factors of i.v. iron administration are 
the number and duration of required infusions ( table 2 ). 
Accordingly, lowest total administration costs per 1,000 
Table 2.  Treatment regimen and i.v. administration costs of 1,000 mg iron over a 10-week treatment period based on SmPC and the 
Swiss tariff list (TARMED)
FG Iron dextran Iron sucrose FCM
Treatment regimen
Maximum approved dose per administration 62.5 mg in 10 min 100 mg in 2 min 200 mg in 10 min 200 mg push i.v.
1,000 mg in 7 h 500 mg in 3.5 h 1,000 mg in 15 mina
Cost of administration
Administration scheme 62.5 mg in 10 min 1,000 mg in 7 h 500 mg in 3.5 h 500 mg in 15 minb
Sessions needed (excluding loading dose), n 16 1 2 2
Cost of test dose, EUR 0 37 0 0
Administration cost, EUR 680 290 251 85
Drug cost, EUR 114 205 228 278
Total cost of administration, EUR/1,000 mg iron 794 495 479 363
S mPC = Summary of Product Characteristics.
a Maximum 15 mg/kg body weight.
b The analysis assumed two 500-mg injections, which represents the administration scheme of current clinical practice.
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mg iron were estimated for FCM (assuming 2 infusions 
of 500 mg iron each). FCM is a dextran-free i.v. iron prep-
aration that allows rapid administration of up to 1,000 
mg iron without need for a test dose. Therefore, FCM 
showed a favorable cost profile although direct drug costs 
for this substance were higher than for the other i.v. iron 
preparations. This result requires verification under rou-
tine practice conditions.
 Given the clinical advantages of i.v. iron supplementa-
tion and a potential yet unproven economic benefit, fur-
ther studies on the potential of i.v. iron to reduce ESA-
related cost in routine treatment of anemic cancer pa-
tients are warranted.
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